Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Telisotuzumab adizutecan by AbbVie for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
Telisotuzumab adizutecan by AbbVie for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Recurrent Head And Neck Squamous Cell...
Telisotuzumab adizutecan by AbbVie for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
Telisotuzumab adizutecan by AbbVie for Gastric Cancer: Likelihood of Approval
Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
Telisotuzumab adizutecan by AbbVie for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According...
Telisotuzumab adizutecan by AbbVie for Renal Cell Carcinoma: Likelihood of Approval
Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Renal Cell Carcinoma. According to GlobalData,...